Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
Opthea Limited (ASX:OPT; NASDAQ:OPT) announced an 'Ask the Expert' conference call with Professor Jason S. Slakter on December 13, 2022. The session will cover Opthea's clinical trial programs for treating retinal diseases, specifically focusing on the management of wet AMD and the role of OPT-302. Participants can submit questions in advance. The company is developing therapies addressing unmet needs in wet age-related macular degeneration and diabetic macular edema, with OPT-302 undergoing pivotal Phase 3 trials.
- OPT-302 is in pivotal Phase 3 clinical trials to enhance treatment efficacy for wet AMD.
- The upcoming conference call offers insights from a leading expert, potentially boosting investor confidence.
- The inherent risks of biotechnology investments are highlighted, including high failure rates in clinical trials.
MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an “Ask the Expert” conference call with Professor Jason S. Slakter, M.D. on Tuesday 13th December 6:30pm – 7:30pm EST USA (Wednesday 14th December 10:30am – 11:30am AEDT).
Prof Slakter is a board certified Retinal and Macular Disease Specialist, Clinical Professor of Ophthalmology at New York University School of Medicine, and partner of Vitreous Retina Macula Consultants of New York. Prof Slakter will present an overview of Opthea’s Phase 2b and Phase 3 clinical trial program followed by a Question and Answer session on the current management of wet AMD patients and the potential role of OPT-302 within the treatment landscape.
Participants are invited to submit questions via this link prior to the conference call. Please click here to register for the virtual meeting which will be held via Zoom.
About Opthea Limited
Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.
Inherent risks of Investment in Biotechnology Companies
There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.
Authorized for release to ASX by Megan Baldwin, CEO & Managing Director
Company & Media Enquiries:
| U.S.A. & International: Timothy E. Morris, CFO Opthea Limited Tel: +1 650-400-6874 | Australia: Rudi Michelson Monsoon Communications Tel: +61 (0) 3 9620 3333 | |
| Media: Hershel Berry Blueprint Life Science Group Tel: +1 415 505 3749 hberry@bplifescience.com | ||
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com
FAQ
What is the purpose of the Opthea conference call on December 13, 2022?
Who is presenting at the Opthea conference call?
What is the current status of OPT-302?
What does the press release say about investment risks in biotechnology?
